Subscribe to Newsletter

Content by Stephanie Vine:

Business & Regulation Technology and Equipment

The Times They Are a-Changin’

| Stephanie Vine

What impact will Brexit, a new US President, and a flood of new technologies have on the industry?

Manufacture Vaccines

Plague Prevention

| Stephanie Vine

Bioterrorism concerns prompt the UK government to fund development of a vaccine for plague.

Manufacture Business Practice

And the Facility of the Year is…

| Stephanie Vine

Genentech’s Cell Culture Biologics Drug Substance Plant 2 in Vacaville, California.

Business & Regulation Packaging

Serialization Standardization

| Stephanie Vine

A consortium of vendors and pharma companies search for a single, serialization standard.

Manufacture Business Practice

When Free is Not Good Enough

| Stephanie Vine

Why has Médecins Sans Frontières rejected an offer of free vaccines from Pfizer?

Business & Regulation Business Practice

And a New Era at GSK

| Stephanie Vine

Emma Walmsley is chosen as GlaxoSmithKline's new CEO.

Business & Regulation Business Practice

End of an Era at EFPIA

| Stephanie Vine

Richard Bergstrom has resigned from EFPIA - who will replace him?

Business & Regulation Business Practice

CPhI in Numbers

| Stephanie Vine

Our infographic looks at how the CPhI trade show has grown over the years.

Business & Regulation Business Practice

Public Enemy

| Stephanie Vine

Why is the pharma industry so despised when it has saved countless lives?

Business & Regulation Business Practice

Mylan’s Media Storm

| Stephanie Vine

Mylan introduces new schemes to help tackle EpiPen costs for patients, as well as plans for a new direct-to-patient distribution model

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register